Understanding the US Safe Harbor, and Regulatory and Research Safe Harbors in the EU/Canada

Appreciating the scope of protection afforded by the Section 271(e)(1) Hatch-Waxman Safe Harbor is vital to pharmaceutical and biotech firms. Moreover, a general understanding of the protections available in the EU and Canada also allows multinational organizations to conduct their research and development efforts in the most infringement-free environment. Fish attorneys Brian Coggio and Ron Vogelspoke about these protections and strategies for doing business in light of them in this one-hour webinar. Topics included:

• What is the Safe Harbor and its origins and scope?
• What is the impact of recent rulings?
• What pre- and post-approval activities are protected under the Safe Harbor?
  • API suppliers
  • Stockpiling
  • Research tools
• How do the Bolar Exception and Bolar Exemption affect research and development efforts in the EU and Canada?
• What is the broad European research exemption?

If you are interested in gaining a better understanding of the domestic and multinational protections available to pharmaceutical or biotech companies, this complimentary webinar is for you.

To download the slides to this webinar, please click here.